Repurposing FDA-approved drugs for SARSCoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

Wenyu Fu; Yujianan Chen; Kaidi Wang; Aubryanna Hettinghouse; Wenhuo Hu; Jing-Quan Wang; Zi-Ning Lei; Zhe-Sheng Chen; Kenneth A. Stapleford; Chuan-ju Liu

doi:10.1007/s13238-020-00803-w

Protein Cell ›› 2021, Vol. 12 ›› Issue (7) : 586 -591. DOI: 10.1007/s13238-020-00803-w

LETTER

Repurposing FDA-approved drugs for SARSCoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

Author information +

History +

PDF (811KB)

Cite this article

Download citation ▾

Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi-Ning Lei, Zhe-Sheng Chen, Kenneth A. Stapleford, Chuan-ju Liu. Repurposing FDA-approved drugs for SARSCoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. Protein Cell, 2021, 12(7): 586-591 DOI:10.1007/s13238-020-00803-w

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Castañeda-Arriaga R, Pérez-González A, Galano A (2018) Chemical Protectors against the Toxic Effects of Paracetamol (Acetaminophen) and Its Meta Analogue: Preventing Protein Arylation. ACS Omega 3:18582–18591

[2]	De Flora S, Grassi C, Carati L (1997) Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 10:1535–1541

[3]	Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J Jr (2010) N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 79:413–420

[4]	Ghezzi P, Ungheri D (2004) Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol 17:99–102

[5]	Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, Rezelj VV, Guo JZ, Swaney DL (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583:459–468

[6]	Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP (2020) Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients 12:988

[7]	Gu C, Wu Y, Guo H, Zhu Y, Xu W, Wang Y, Sun Z, Cai X, Li Y, Liu J (2020) Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 infection. bioRxiv, 2020.2004.2030.071290

[8]	Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289–293

[9]	Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M (2020) Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368:860–868

[10]	Mitchell F (2020) Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet Diabetes Endocrinol. 8:570

[11]	Nolin TD, Ouseph R, Himmelfarb J, McMenamin ME, Ward RA (2010) Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol 5:1588–1594

[12]	Poe FL, Corn J (2020) N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med Hypotheses 143:109862

[13]	Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L (2020) A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature 584:120–124

[14]	Zemb P, Bergman P, Camargo CA Jr, Cavalier E, Cormier C, Courbebaisse M, Hollis B, Minisola S, Pilz S, Pludowski P (2020) Vitamin D deficiency and COVID-19 pandemic. J Glob Antimicrob Resist 29:133–134

[15]	Zhang C, Cui M, Cui Y, Hettinghouse A, Liu CJ (2019) A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction. J Vis Exp 27, doi: 10.3791/59656